All
FDA Approves Cinvanti Injection for Chemotherapy-Induced Nausea and Vomiting
March 2nd 2019The U.S. Food and Drug Administration has expanded the approval of Cinvanti injectable emulsion to include a two-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
FDA Advisory Committee Votes Against Accelerated Approval of Selinexor for Multiple Myeloma
February 27th 2019The Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 recommending the FDA delay approval of selinexor for the treatment of patients with penta-refractory multiple myeloma until further trial data are available.
FDA Grants Priority Review to Revlimid Plus Rituxan for Indolent Non-Hodgkin Lymphoma
February 27th 2019The Food and Drug Administration granted a priority review to Revlimid (lenalidomide) plus Rituxan (rituximab) for the treatment of patients with previously treated follicular lymphoma and marginal zone lymphoma.
Topline Results Support Quicker, Convenient Administration of Darzalex in Myeloma Therapy
February 27th 2019Outcomes associated with subcutaneous injections of Darzalex (daratumumab) appeared similar to IV administration in patients with relapsed or refractory myeloma, according to the phase 3 COLUMBA trial.
The Administration's Drug Rebate Proposal: An Opportunity to Put Patients First
February 26th 2019Of all the health care regulations coming out of the current administration, the recent drug rebate proposal presents a new opportunity to significantly lower out-of-pocket prescription drug costs for Medicare patients. But like most things in health care, there is more complexity to the administration’s proposed changes to pharmaceutical company rebates than initially meets the eye.